However, during ICI treatment, resistance to ICIs can emerge due to excessive expression of PD-L1 antibodies induced by an immune response to cancer, leading to a decrease in CD8+ T lymphocytes, or due to tumor-induced changes in the tumor microenvironment (TME) [12]. The gene discussed is CD8A; the disease is neoplasm.